LENTECHS is a clinical-stage, ophthalmic medical device company dedicated to improving vision through breakthrough contact lens technology. APIOC® is a patented, first-of-its-kind line of soft, suspended contact lens designed to deliver exceptional, glasses-like vision at all distances. Lentechs is focused on the 120 million US patients and 2 billion worldwide living with presbyopia and presbyopia with astigmatism. The APIOC design is completely different from current soft, multifocal contact lenses which only offer simultaneous vision correction and cause some visual compromise, making lenses more challenging to adapt to for some patients. APIOC has been designed especially with the presbyopia patient in mind. The majority of these patients wear spectacles but would prefer to wear contact lenses and, among these patients who do wear contact lenses, many do not receive the desired results from currently available technology. With a slightly more relaxed fit than traditional lenses, APIOC’s breakthrough design consists of unique, patented features which suspend the lens behind the upper eyelid. APIOC is first and foremost designed to utilize the eye’s anatomy rather than conform to it. Unlike traditional contact lenses, our APIOC lens is suspended behind the upper eyelid, allowing for free, translational (up and down) eye movement, behind the rotationally stable, centered contact lens. By allowing the eye to freely move behind the APIOC lens, wearers can access the specific prescription needed for each visual distance correction, achieving glasses-like vision with the freedom of a contact lens. The Team, Board of Directors and Medical Advisory Board are highly experienced. Recently completed studies in humans give a strong signal of efficacy and support the expected improved vision versus currently available multifocal contact lenses for presbyopia. Lentechs is in the process of raising a Series B to perform head-to-head randomized controlled clinical trials versus the market leading multifocal contact lenses for presbyopia. This could lead to an independent commercial launch or sale.